Minke W. Lucas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minke W. Lucas has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Alexander C.J. van Akkooi
Melanoma Institute Australia, Wollstonecraft, Sydney, NSW, Australia; University of Sydney, Faculty of Medicine and Health, Camperdown, NSW, Australia; Royal Prince Alfred Hospital, Institute of Academic Surgery, Camperdown, NSW, Australia
2 shared publicationsChristian U. Blank
Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; Department Hematology and Oncology, University Clinic Regensburg (UKR), Germany
2 shared publicationsGeorgina V. Long
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
2 shared publicationsJohn B.A.G. Haanen
Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, the Netherlands; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2 shared publications- Lonneke V. van de Poll-Franse
Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
2 shared publications - Mees Diederik Egeler
Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 15 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115640
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma
- 15 July 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 227, 115640
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma
- Top Cited Papers
- 7 November 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (18) , 1696-1708
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Phase 1-2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma, in a 1:1 ratio, to receive two cycles of neoadjuvant ipilimumab plus nivolumab and then undergo surgery or to undergo surgery and then receive 12 cycles of adjuvant nivolumab. Only the patients in the neoadjuvant group who had a partial response or nonresponse received subsequent adjuvant treatment. The primary end point was event-free survival. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% among patients in the neoadjuvant group who had a major pathological response, 76.1% among those who had a partial response, and 57.0% among those who had a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of the patients in the neoadjuvant group and in 14.7% in the adjuvant group. Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.).
- 7 November 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (18) , 1696-1708
Top Cited PapersNeoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Phase 1-2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma, in a 1:1 ratio, to receive two cycles of neoadjuvant ipilimumab plus nivolumab and then undergo surgery or to undergo surgery and then receive 12 cycles of adjuvant nivolumab. Only the patients in the neoadjuvant group who had a partial response or nonresponse received subsequent adjuvant treatment. The primary end point was event-free survival. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% among patients in the neoadjuvant group who had a major pathological response, 76.1% among those who had a partial response, and 57.0% among those who had a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of the patients in the neoadjuvant group and in 14.7% in the adjuvant group. Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.).